<DOC>
	<DOCNO>NCT00002476</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know radiation therapy plus chemotherapy effective radiation therapy alone treat patient advanced head neck cancer . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy without chemotherapy treat patient advanced head neck cancer .</brief_summary>
	<brief_title>Radiation Therapy With Without Chemotherapy Treating Patients With Advanced Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether addition methotrexate ( MTX ) VBMF ( vincristine/bleomycin/methotrexate/fluorouracil ) radiotherapy advance carcinoma head neck ( without primary surgery ) influence locoregional control prolongs survival . II . Determine whether effect locoregional control survival apparent chemotherapy give follow radiotherapy whether increased chemotherapy give time . III . Determine , special randomization patient cancer oral cavity oropharynx , whether neck irradiation improve locoregional control survival . OUTLINE : Randomized study . Patients without prior surgery randomize 1:2 Arms I : II-IV , prior surgery randomize 1:1 Arms I II . Patients tumor oral cavity oropharynx may elect additional randomization Arms V VI receive irradiation primary accord Manchester regimen . Arm I : Radiotherapy . Irradiation primary and/or lymph node accord 1 2 regimen ( Manchester 3-week schedule SECOG 6-week schedule ) use megavoltage equipment . Arm II : Radiotherapy plus Concurrent Single-agent 4-Drug Combination Chemotherapy Leucovorin Rescue . Involved-field irradiation Arm I ; plus Methotrexate , MTX , NSC-740 ; Leucovorin calcium , CF , NSC-3590 ; VBMF : Vincristine , VCR , NSC-67574 ; Bleomycin , BLEO , NSC-125066 ; MTX ; Fluorouracil , 5-FU , NSC-19893 ; CF . Arm III : Radiotherapy plus Subsequent Single-agent 4-Drug Combination Chemotherapy Leucovorin Rescue . Involved-field irradiation Arm I ; plus MTX VBMF ; CF . Arm IV : Radiotherapy plus Concurrent Subsequent Single-agent 4-Drug Combination Chemotherapy Leucovorin Rescue . Involved-field irradiation Arm I ; plus MTX VBMF ; CF . Arm V : Radiotherapy . Neck node irradiation use megavoltage equipment . Arm VI : Observation . No nodal irradiation . PROJECTED ACCRUAL : At least 1,000 patient enter .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell cancer head neck suitable treatment radiotherapy T2 , T3 , T4 primary lesion Any N No distant metastasis May also anaplastic carcinoma , verrucous carcinoma , transitional cell carcinoma ( 1/97 ) No occult primary ( 1/97 ) No adenocarcinoma , lymphoma , melanoma ( 1/97 ) Synchronous head neck tumor eligible ( tumor bad prognosis enter study ) ( 1/97 ) Patients receive surgery neck node must randomize surgery patient ( 1/97 ) Patients tumor oral cavity oropharynx may additionally elect randomization nodal irradiation vs. therapy provide second primary PATIENT CHARACTERISTICS : Age : 75 patient elect participation nodal vs. nodal irradiation portion study Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Fit protocol treatment option Willing receive protocol treatment option Prior malignancy allow provided treating clinician considers patient cure PRIOR CONCURRENT THERAPY : Biologic therapy : No prior therapy Chemotherapy : No prior therapy Endocrine therapy : No prior therapy Radiotherapy : No prior therapy Surgery : Prior biopsy excision allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II verrucous carcinoma oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage II verrucous carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>